ReviewJournal of immunology research2015
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
Review in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 62 citations in OpenAlex.
- Significance of Gelsolin Superfamily Genes in Diagnosis, Prognosis and Immune Microenvironment Regulation for Endometrial Cancer.Cancer medicine · 2025Article
- Tumor suppressor function of RBMS3 overexpression in EOC associated with immune cell infiltration.Heliyon · 2024Article
- Comprehensive multi-omics analysis of tryptophan metabolism-related gene expression signature to predict prognosis in gastric cancer.Frontiers in pharmacology · 2023Article
- Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer.International journal of molecular sciences · 2022Review
- Review
- Construction of an immune-related ceRNA network in cervical cancer based on HPV E6 splicing.Frontiers in oncology · 2022Article
- Overexpression ofDisease markers · 2022Article
- The role of nanomaterials in enhancing natural product translational potential and modulating endoplasmic reticulum stress in the treatment of ovarian cancer.Frontiers in pharmacology · 2022Review
- Comprehensive analysis of angiogenesis subtype of squamous cell carcinoma.World journal of surgical oncology · 2021Article
- Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.Cells · 2021Article
- Integrated Analysis of Ferroptosis-Related Biomarker Signatures to Improve the Diagnosis and Prognosis Prediction of Ovarian Cancer.Frontiers in cell and developmental biology · 2021Article
- Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.Frontiers in pharmacology · 2021Review
- Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?Journal of clinical medicine · 2020Review
- Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.OncoTargets and therapy · 2020Review
- Immune check-point in endometrial cancer.International journal of clinical oncology · 2019Review
- VISTA expressed in tumour cells regulates T cell function.British journal of cancer · 2019Article
- Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.Oncology letters · 2018Article
- Natural killer cells inhibit metastasis of ovarian carcinoma cells and show therapeutic effects in a murine model of ovarian cancer.Experimental and therapeutic medicine · 2018Article
- Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.Journal of ovarian research · 2018Article
- Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Journal of gynecologic oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the most important cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease. Although surgery and chemotherapy can improve survival rates, it is necessary to integrate alternative strategies to improve the outcomes. Advances in understanding the role of immune system in the pathogenesis of cancer have led to the rapid evolvement of immunotherapy, which might establish a sustained immune system response against recurring cancer cells. Recently, it has emerged that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called "immune checkpoints," which turn off the immune system. Similarly, cancer cells are able to use these checkpoints to avoid immune control and rejection. Inhibition of these inhibitory pathways represents a potent strategy in the fight against cancer and is currently under investigation with encouraging results in some cancers, such as melanoma. In ovarian cancer researches are still in an early phase, but with promising results. In this review we will explore the rationale of immunotherapy in ovarian cancer with a special focus on these emerging molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.